SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Biocon to launch psoriasis drug in July this year

29 Apr 2013 Evaluate

Biocon, Asia's premier biotechnology company, plans to launch its novel biologic drug Itolizumab branded as ‘Alzumab’ to be used for the treatment of chronic plaque psoriasis in the country. The biotechnology major is planning to launch it in month of July this year. The drug will be manufactured at the company’s biopharma manufacturing facility at Biocon Park in Bangalore.

In January 2013, the company received marketing authorization for Itolizumab from the Drugs Controller General of India. The company has also completed a pre-IND (Investigational New Drug) meeting for Itolizumab with the US Food and Drug Administration as it plans for a global clinical development of the new medicine. This is company’s second novel biologic developed in India. BioMab EGFR, an anti-cancer monoclonal antibody being the first.

Psoriasis is an inflammatory auto-immune skin disease that follows a typical relapsing and remitting course with the disease affecting 2-3% of the total population in the country. The global market for psoriasis treatments is estimated to cross $8 billion by 2016.

Biocon is India’s premier biotechnology company with a strategic focus on biopharmaceuticals and research services. Biocon produces anti-diabetic agents like Acarbose, Pioglitazone, Repaglinides and Rosiglitazone. In the biological segment it produces Insulin, Erythropoietin (EPO), Filgrastim (GCSF), Streptokinase and Monoclonal Antibodies.

Biocon Share Price

360.85 2.65 (0.74%)
20-Apr-2026 12:53 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1670.40
Dr. Reddys Lab 1236.50
Cipla 1234.30
Zydus Lifesciences 942.40
Lupin 2332.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×